COLOGUARD TEST: A POSSIBLE ALTERNATE TO COLONOSCOPY?
Abstract
Dear Editor,Colorectal cancer (CRC), is the third most common cancer affecting close to 10,00,000 people worldwide causing second most cancer-related deaths with 6,55,000 death toll per year.1 Recommended by The U.S. Preventive Services Task Force (USPSTF) in average-risk adults between 50–75 years of age, regular screening through colonoscopy every 10 years or yearly faecal occult blood testing can prevent at least 60% of deaths from colorectal cancer.2 Current epidemiologic data on CRC in Pakistan is limited but according to a study3 there has been a 41% increase in incidence between 1995 and 1999 in males indicating a higher incidence at present. But unfortunately, CRC screening is not done routinely in our country. Lack of patient acceptance particularly among females, cultural barriers, financial limitation, lack of resources, lack of physician/public awareness and lack of epidemiological research are paramount reasons for this.4The U.S. Food and Drug Administration in 2014 approved the first stool-DNA colorectal screening test-The Cologuard test.2 It is a multi-target test that detects the presence of haemoglobin and colorectal cancer-related DNA mutations in shed abnormal cells using nine biomarkers. Repeated once every three years, this screening test may reveal even the presence of an advanced precancerous lesion from the sample send from the privacy of home. Compared to colonoscopy-the most sensitive of all, the cologuard test requires no bowel preparation, dietary changes or sedation. Conversely colonoscopy being invasive and less acceptable to patients, requires an in-patient setting with an experienced personnel and costs around $100 in our country. The other relatively inexpensive guaiac-based-FOBT needs to be repeated every year and does not detect some cancers.5 Effectiveness of cologuard test was established in a clinical trial that screened 10,023 asymptomatic adults between 50 and 84 years of age. The trial compared cologuard test to the faecal immunochemical test (FIT), another non-invasive screening test. The sensitivity for detecting CRC using DNA test and FIT was found to be 92.3% and 73.8% (p=0.002) respectively. For advanced precancerous lesions sensitivity of DNA test was 42.4% and for FIT was 23.8% (p<0.001). Although with lower specificity, DNA testing had a 27% relative increase in the detection rate of stage I–III colorectal cancers and a 78% relative increase in advanced precancerous lesions compared to FIT.6 However a positive result with either test should be followed by a diagnostic colonoscopy.In conclusion, offering a convenient, non-invasive and inexpensive screening option with a high sensitivity for curable-stage cancer may improve uptake by the people in our country. With appropriate physician and public awareness, cologuard test can be integrated into colon cancer screening program in our country, specifically helpful for those who refuses to undergo colonoscopy.Keywords: Cologuard test; Stool-DNA test; FIT- DNA test; Colorectal cancer; CRC; ColonoscopyReferences
Zhao R. Perspectives on the treatment of colorectal carcinoma. World J Gastrointest Oncol 2010;2(5):229–34.
FDA approves first non-invasive DNA screening test for colorectal cancer [Internet]. U.S. Food and Drug Administration. 2014 [cited 2017 Jan 17]. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm409021.htm
Bhurgri Y, Bhurgri A, Nishter S, Ahmed A, Usman A, Pervez S, et al. Pakistan-country profile of cancer and cancer control 1995–2004. J Pak Med Assoc 2006;56(3):124–30.
Ahmed F. Barriers to colorectal cancer screening in the developing world: The view from Pakistan. World J Gastrointest Pharmacol Ther 2013;4(4):83–5.
Tests to Detect Colorectal Cancer and Polyps [Internet]. National Cancer Institute. 2016 [cited 2017 Jan 17]. Available from: https://www.cancer.gov/types/colorectal/screening-fact-sheet.
Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370(14):1287–97.
Published
Issue
Section
License
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
